Participated · Series E · Mar 2025

Cardiac Dimensions develops minimally invasive treatments for heart failure and functional mitral regurgitation, with its flagship Carillon Mitral Contour System designed as a catheter-based therapy to restore natural mitral valve function. The Carillon device aims to reduce mitral regurgitation, improve quality of life, and has been associated in clinical studies with extended survival; it can be used as a front-line option and does not preclude future therapies. The company says the procedure promotes favorable left ventricular remodeling while avoiding damage to mitral valve leaflets. Cardiac Dimensions plans to use new financing to complete the EMPOWER Trial U.S. pivotal study and to continue commercialization and global commercial expansion of the Carillon therapy. The company recently closed an oversubscribed $53 million Series E financing led by Ally Bridge Group with significant participation from existing investors. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia; and Frankfurt, Germany. Cardiac Dimensions develops the Carillon Mitral Contour System, a minimally invasive, non-surgical device intended to restore mitral valve function and induce favorable left ventricular remodeling to reduce mitral regurgitation. The Carillon therapy is an indirect, no-touch annuloplasty designed to improve quality of life and extend survival and can be used alongside other heart-failure treatments. The device has obtained CE Mark and Therapeutic Goods Approval (TGA) and is approved for sale in Europe and Australia, while it is considered an investigational device in the U.S. To date, thousands of patients have been treated with the Carillon system worldwide, and positive safety and performance data encompassing more than 350 patients have been published from four studies and a real-world registry. Cardiac Dimensions is currently enrolling the U.S. EMPOWER pivotal trial and intends to use new financing to accelerate enrollment, broaden treatment to earlier-stage patients, and expand commercial sales in European markets with full reimbursement. The company has operations in Kirkland, Washington; Sydney, Australia; and Frankfurt, Germany. Cardiac Dimensions develops minimally invasive treatments for functional mitral regurgitation (FMR), centered on its Carillon Mitral Contour System®. The Carillon System uses a right-heart, transcatheter approach via the coronary sinus to reshape the mitral apparatus. The device is CE-marked (0344) and has been implanted in over 1,200 patients across the U.S., Europe, Australia, Turkey and the Middle East. The company is studying the device in the pivotal CARILLON Trial and it remains investigational in the United States. Management, led by CEO Rick Wypych, plans to accelerate commercial sales in Europe and expand into other geographies such as Australia. Recent regulatory progress includes approval from Australia’s Therapeutic Goods Administration for commercial use in FMR patients with mild to severe mitral regurgitation. The company closed a $17.5M Series C to support these commercial efforts. Cardiac Dimensions develops the Carillon Mitral Contour System, a minimally invasive, catheter-based device intended to treat functional mitral regurgitation by reducing the dilated mitral annulus. The company is building clinical evidence through multiple studies, including completing follow-up and publication of the randomized, double-blinded REDUCE FMR global study and continuing enrollment in The CARILLON U.S. pivotal trial. The Carillon System has CE Mark clearance and is available in certain European markets, including Turkey, the Netherlands and Italy. More than 850 patients worldwide have been treated with the device across completed international studies (AMADEUS, TITAN, TITAN II) and ongoing trials. Cardiac Dimensions intends to use new financing to support continued trial enrollment, complete the REDUCE FMR follow-up/publication, and expand its presence in global markets. The company has operations in Kirkland, Sydney and Frankfurt. Cardiac Dimensions develops minimally invasive treatment modalities for heart failure and related cardiovascular conditions, with an initial technology platform called the CARILLON Mitral Contour System designed to address functional mitral regurgitation via a percutaneous approach. The company is led by CEO Rick Stewart and is based in Kirkland, Washington; Sydney, Australia; and Frankfurt, Germany. It raised an additional $15.2M in this financing, bringing total capital raised to $43M. Proceeds are planned to fund the REDUCE FMR blinded, randomized clinical trial of a percutaneous mitral repair device in patients with functional mitral regurgitation. The company also intends to expand research and development projects and its commercial operations with the new funding.

Participated · Seed · Jul 2022

DigiBuild offers a suite of digital project management and supply chain tools, including a large supplier database and blockchain-backed single source of truth for construction workflows. Its supplier database (free for suppliers) emphasizes minority- and women-owned firms and environmentally friendly products. The platform integrates ChatGPT to surface contextual information across suppliers, materials, specification books, schedules, and budgets. Leadership says the product has produced measurable savings—one customer saved $600,000 and 600 hours on an 80,000-square-foot project—and has attracted clients such as Brasfield & Gorrie, JR Hospitality, and Baywood Hotels. DigiBuild has 15 employees and participated in Y Combinator. The company plans to scale across the U.S. and internationally, build out its supplier database, onboard more customers, and announce additional investments and larger project participation. DigiBuild builds a blockchain-based platform to digitize construction processes, with a primary product called DigiProcure for material management and procurement. DigiProcure automates administrative processes, lets contractors search, filter, and compare project timeline data, and aims to reduce waste and fraud through advanced data insights. The blockchain layer creates a single source of truth to improve collaboration across parties that otherwise maintain multiple versions of paperwork. The company plans to use new funding to expand product and technical capabilities, improve sales and marketing, and grow its contractor customer base. DigiBuild is remote-first with headquarters in Miami and currently has nine full-time employees; it intends to hire a business development manager, preferably Miami-based.

Led · Equity · Aug 2019

EBR Systems is a Sunnyvale, Calif.-based developer of the WiSE (Wireless Stimulation Endocardially) wireless cardiac pacing technology designed to eliminate the need for cardiac pacing leads. Its initial product aims to remove the need for coronary sinus leads to stimulate the left ventricle in heart failure patients who require cardiac resynchronization therapy (CRT). The company plans future products to address wireless endocardial stimulation for bradycardia and other non-cardiac indications. EBR is conducting the SOLVE CRT multi-center, randomized, double-blinded, prospective international study to assess safety and efficacy of WiSE in support of a U.S. FDA premarket approval (PMA) application. The SOLVE CRT study is enrolling 350 heart failure patients who have failed to respond to, or cannot receive, conventional CRT and was expected to complete enrollment in 2020. EBR intends to use the recently raised funds to complete SOLVE CRT enrollment and to prepare for commercialization of the WiSE CRT System. Leadership noted in the article includes President and CEO John McCutcheon and Executive Chairman Allan Will (former Chairman and CEO). EBR Systems develops the WiSE (Wireless Stimulation Endocardially) wireless cardiac pacing system that implants a tiny electrode directly in the left ventricle to pace heart failure patients who have failed or cannot receive conventional CRT. The system aims to eliminate the need for coronary sinus leads and their associated complications by providing endocardial pacing via a rice-grain-sized implant. The company raised $50 million to conduct the SOLVE-CRT pivotal trial intended to establish safety and efficacy in support of U.S. Food and Drug Administration approval. Separately, EBR received CE Mark approval for its second-generation wireless transmitter, which is half the size of the first-generation device, extends battery life and enables a simpler, less-invasive implantation; initial cases were performed at four European clinical centers. Future products are planned to address wireless endocardial stimulation for bradycardia and other non-cardiac indications. The company's wireless pacing system is not currently available for commercial sale in the United States. EBR Systems is a Sunnyvale, CA-based developer of a wireless cardiac pacing system designed to eliminate the need for cardiac pacing leads. Its initial product eliminates the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring CRT. Future product plans include wireless endocardial stimulation for bradycardia and applications in other non-cardiac indications. The company’s system is not yet available for commercial sale and is subject to obtaining a CE mark for Europe and U.S. IDE approval for clinical study. Led by Chairman and CEO Allan Will, EBR intends to use the recent funding for clinical studies and regulatory filings and has commitments toward a second-quarter closing. EBR Systems develops a new-style pacemaker and other cardiac pacing devices. The company raised a $35 million third round of financing to advance its product toward clinical trials. Delphi Ventures led the round, with existing investors De Novo Ventures, Frazier Healthcare Ventures, Split Rock Partners and SV Life Sciences participating. The Sunnyvale, Calif.-based company had previously raised $27 million across its first two rounds. The new capital is intended to support clinical testing and regulatory steps for its pacing device.

Participated · Series B · Feb 2018

Simplify Medical makes the Simplify® cervical artificial disc, an MRI-friendly PEEK-on-ceramic device designed to minimize post-operative CT scans and reduce patient exposure to ionizing radiation. The Simplify Disc features no metal articulating components for low wear, low-height implant options, and a straightforward three-step implantation; it is considered MRI-conditional. The device has received the CE Mark and is commercially available in select European markets, with early clinical data showing substantial pain and functional improvement. The company is using Series B funding to complete two ongoing U.S. pivotal trials — one-level and two-level cervical implantation studies — and to support commercialization outside the U.S. Simplify Medical completed an oversubscribed second tranche of its Series B, bringing the round to $44.25 million. The company is based in Sunnyvale, California. Simplify Medical develops the Simplify® cervical artificial disc using MRI-friendly materials intended to avoid metal artifact and reduce the need for CT and ionizing radiation. The device is designed to avoid metal wear and offers a low-profile implant to expand patient eligibility. The Simplify Disc has received the CE Mark and has been used to treat more than 700 patients outside the U.S. over the last three years, with early clinical data showing substantial improvements in pain scores and function. Simplify Medical is conducting two U.S. pivotal trials: a prospective two-level trial of up to 200 patients at up to 15 centers comparing two-level implantation with two-level fusion, and a one-level trial using a historical nonconcurrent control group. The company will use new funding to complete these ongoing pivotal trials as part of its pathway toward availability for U.S. patients. Simplify Medical is located in Sunnyvale, California.